NCT03144635View on ClinicalTrials.gov

A Study for G1b CHC Patients With CKD-3 Treated With Grazoprevir Plus Elbasvir

PHASE4CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

April 1, 2017

Primary Completion Date

December 31, 2017

Study Completion Date

September 20, 2018

Conditions
Hepatitis C ViralChronic Kidney Disease stage3
Interventions
DRUG

Grazoprevir plus Elbasvir

An oral dose of 100 mg/day of grazoprevir as well as an oral dose of 50 mg/day of elbasvir for 12 weeks.

Trial Locations (1)

812-8582

Kyushu University Hospital, Fukuoka

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Kyushu University

OTHER

NCT03144635 - A Study for G1b CHC Patients With CKD-3 Treated With Grazoprevir Plus Elbasvir | Biotech Hunter | Biotech Hunter